PMID- 29536426
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20201001
IS  - 1869-6953 (Print)
IS  - 1869-6961 (Electronic)
IS  - 1869-6961 (Linking)
VI  - 9
IP  - 2
DP  - 2018 Apr
TI  - Pioglitazone Improved Insulin Sensitivity and First Phase Insulin Secretion Among 
      Obese and Lean People with Diabetes: A Multicenter Clamp Study.
PG  - 815-826
LID - 10.1007/s13300-018-0401-9 [doi]
AB  - INTRODUCTION: To investigate the effects of pioglitazone (PIO) on insulin 
      resistance and first phase insulin secretion among obese and lean Chinese people 
      with type 2 diabetes mellitus (T2DM). METHODS: Sixty-eight drug-naive patients 
      with T2DM were treated with PIO for 16 weeks. Before and after the treatment, 
      insulin sensitivity was evaluated by the euglycemic hyperinsulinemic clamp test. 
      Plasma insulin levels at 0, 3, 5, 7, and 10 min during intravenous glucose 
      tolerance test were determined to calculate the first phase insulin secretion and 
      pancreatic beta-cell function. Circulating adiponectin levels were quantified. 
      RESULTS: In both the lean and the obese patients with T2DM, the reduction of 
      HbA(1c) following the PIO treatment was more than 1% (P < 0.001) and glucose 
      infusion rate, acute insulin response, glucose disposal index, and beta-cell glucose 
      sensitivity increased significantly (P < 0.001). A multiple linear regression 
      analysis showed that the improvements of first phase insulin secretion and 
      insulin sensitivity were independently associated with the changes of HbA(1c), 
      but the change of first phase insulin secretion exhibited a higher correlation 
      coefficient (R(2) = 0.20, P = 0.001) than the change of insulin sensitivity did 
      (R(2) = 0.07, P = 0.040). The PIO treatment led to a significant increase in 
      adiponectin levels only in the obese group (P < 0.05). CONCLUSION: A 16-week 
      treatment of PIO significantly increased insulin sensitivity and beta-cell function 
      in the lean group as well as in the obese group among Chinese T2DM patients, 
      demonstrating that both lean and obese diabetic adults would profit from PIO. 
      TRIAL REGISTRATION: The ChiCTR registry number is ChiCTR-OPC-17011571. FUNDING: 
      Takeda Pharmaceutical Co. Ltd. and Pfizer Pharmaceutical Co. Ltd.
FAU - Qian, Xin
AU  - Qian X
AD  - Endocrinology and Cardiovascular Diseases Center, Fuwai Hospital, Chinese Academy 
      of Medical Sciences, No. 167 North Lishi Road, Xicheng District, Beijing, China.
FAU - Wang, Hui
AU  - Wang H
AD  - Endocrinology and Cardiovascular Diseases Center, Fuwai Hospital, Chinese Academy 
      of Medical Sciences, No. 167 North Lishi Road, Xicheng District, Beijing, China.
FAU - Yang, Gangyi
AU  - Yang G
AD  - Department of Endocrinology, The Second Affiliated Hospital, Chongqing Medical 
      University, No. 76 Linjiang Road, Chongqing, China.
FAU - Gao, Zhengnan
AU  - Gao Z
AD  - Department of Endocrinology, Dalian Municipal Central Hospital, No. 42 Xuegong 
      Street, Shahekou District, Dalian, China.
FAU - Luo, Yong
AU  - Luo Y
AD  - Department of Endocrinology, Chongqing Three Gorges Central Hospital, No. 165 
      Xincheng Road, Wanzhou District, Chongqing, China.
FAU - Dong, Aimei
AU  - Dong A
AD  - Department of Endocrinology, Peking University First Hospital, No. 8 Xishiku 
      Road, Xicheng District, Beijing, China.
FAU - Zhang, Fang
AU  - Zhang F
AD  - Department of Endocrinology, Peking University Shenzhen Hospital, No. 1120 
      Lianhua Road, Futian District, Shenzhen, China.
FAU - Xu, Mingtong
AU  - Xu M
AD  - Department of Endocrinology, Second Affiliated Hospital of Sun Yat-sen 
      University, No. 107 Yanjiang West Road, Guangzhou, China.
FAU - Liu, Shiping
AU  - Liu S
AD  - Department of Endocrinology, The Second Xiangya Hospital of Central South 
      University, No. 139 Renmin Middle Road, Changsha, Hunan, China.
FAU - Yang, Xin
AU  - Yang X
AD  - Department of Information Systems, Statistics, and Management Science, 
      Culverhouse College of Commerce and Business Administration, The University of 
      Alabama, Tuscaloosa, AL, USA.
FAU - Chen, Yanyan
AU  - Chen Y
AD  - Endocrinology and Cardiovascular Diseases Center, Fuwai Hospital, Chinese Academy 
      of Medical Sciences, No. 167 North Lishi Road, Xicheng District, Beijing, China.
FAU - Li, Guangwei
AU  - Li G
AD  - Endocrinology and Cardiovascular Diseases Center, Fuwai Hospital, Chinese Academy 
      of Medical Sciences, No. 167 North Lishi Road, Xicheng District, Beijing, China. 
      guangwei_li45@126.com.
LA  - eng
PT  - Journal Article
DEP - 20180313
PL  - United States
TA  - Diabetes Ther
JT  - Diabetes therapy : research, treatment and education of diabetes and related 
      disorders
JID - 101539025
PMC - PMC6104278
OTO - NOTNLM
OT  - First phase
OT  - Insulin resistance
OT  - Insulin secretion
OT  - Pioglitazone
EDAT- 2018/03/15 06:00
MHDA- 2018/03/15 06:01
PMCR- 2018/03/13
CRDT- 2018/03/15 06:00
PHST- 2018/01/15 00:00 [received]
PHST- 2018/03/15 06:00 [pubmed]
PHST- 2018/03/15 06:01 [medline]
PHST- 2018/03/15 06:00 [entrez]
PHST- 2018/03/13 00:00 [pmc-release]
AID - 10.1007/s13300-018-0401-9 [pii]
AID - 401 [pii]
AID - 10.1007/s13300-018-0401-9 [doi]
PST - ppublish
SO  - Diabetes Ther. 2018 Apr;9(2):815-826. doi: 10.1007/s13300-018-0401-9. Epub 2018 
      Mar 13.